Press Release and Investor Presentation
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Ingrevia reported strong Q4 FY26 results with revenue of Rs 1,179 crore (up 12% YoY) and EBITDA of Rs 172 crore (up 11% YoY, up 26% QoQ). PAT came in at Rs 86 crore, up 84% QoQ and 17% YoY. For full year FY26, revenue stood at Rs 4,388 crore (5% growth) with EBITDA of Rs 607 crore (9% growth) and PAT of Rs 278 crore (11% growth). The company achieved its highest quarterly revenue in 14 quarters. Specialty Chemicals remains the dominant segment with 27% EBITDA margins and 21% EBITDA growth in FY26. Nutrition segment showed strong recovery with 21% revenue growth in Q4. The Board recommended a final dividend of Rs 2.50 per share, taking total FY26 dividend to Rs 5 per share. Net debt reduced by 11% YoY to Rs 587 crore, with Net debt/EBITDA improving to 0.99x. Key highlights include successful dispatch from newly constructed Agro CDMO facility, completion of Remidex Pharma acquisition, and 100+ opportunities worth Rs 3,400 crore in the pipeline.
The company delivered a strong Q4 with margin improvement across all three segments. The improving portfolio mix toward higher-margin Specialty Chemicals and Nutrition (now contributing 85%+ of EBITDA), combined with a robust order pipeline and debt reduction, indicates solid execution of the Pinnacle strategy. Management expects sequential growth starting Q1 FY27, which should be positive for the stock.